Larimar Therapeutics Inc (LRMR)

Currency in USD
4.260
+0.540(+14.52%)
Closed·
4.340+0.080(+1.88%)
·
LRMR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected today
LRMR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.6804.330
52 wk Range
1.6109.500
Key Statistics
Prev. Close
3.72
Open
3.71
Day's Range
3.68-4.33
52 wk Range
1.61-9.5
Volume
2.58M
Average Volume (3m)
1.34M
1-Year Change
-50.86%
Book Value / Share
2.25
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LRMR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.600
Upside
+383.57%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Larimar Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Larimar Therapeutics Inc Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics Inc SWOT Analysis


Promising FA Treatment
Larimar's nomlabofusp shows potential as a groundbreaking therapy for Friedreich's ataxia, with clinical trials expanding to include younger patients
Financial Runway
Strong $226M cash position funds operations into 2026, but high R&D expenses and net losses pose challenges to long-term stability
Regulatory Milestones
Explore Larimar's path to BLA submission, with potential accelerated approval based on frataxin level increases and crucial data releases expected
Market Dynamics
Analysts set price targets ranging from $21 to $25, as Larimar navigates competition from approved treatments and pipeline candidates in the FA market
Read full SWOT analysis

Compare LRMR to Peers and Sector

Metrics to compare
LRMR
Peers
Sector
Relationship
P/E Ratio
−3.3x−3.2x−0.5x
PEG Ratio
0.06−0.010.00
Price/Book
2.2x2.6x2.6x
Price / LTM Sales
-8.7x3.3x
Upside (Analyst Target)
-180.1%40.3%
Fair Value Upside
Unlock5.3%4.7%Unlock

Analyst Ratings

11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 20.600
(+383.57% Upside)

Earnings

Latest Release
Aug 14, 2025
EPS / Forecast
-0.41 / -0.48
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

LRMR Income Statement

People Also Watch

2.000
VOR
-0.99%
20.30
SRPT
-0.49%
2.45
INMB
-4.30%
139.23
CRCL
-9.10%
0.350
VYNE
+0.69%

FAQ

What Stock Exchange Does Larimar Therapeutics Inc Trade On?

Larimar Therapeutics Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Larimar Therapeutics Inc?

The stock symbol for Larimar Therapeutics Inc is "LRMR."

What Is the Larimar Therapeutics Inc Market Cap?

As of today, Larimar Therapeutics Inc market cap is 369.32M.

What Is Larimar Therapeutics Inc's Earnings Per Share (TTM)?

The Larimar Therapeutics Inc EPS (TTM) is -1.49.

When Is the Next Larimar Therapeutics Inc Earnings Date?

Larimar Therapeutics Inc will release its next earnings report on 13 Aug 2025.

From a Technical Analysis Perspective, Is LRMR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Larimar Therapeutics Inc Stock Split?

Larimar Therapeutics Inc has split 1 times.

How Many Employees Does Larimar Therapeutics Inc Have?

Larimar Therapeutics Inc has 65 employees.

What is the current trading status of Larimar Therapeutics Inc (LRMR)?

As of 14 Aug 2025, Larimar Therapeutics Inc (LRMR) is trading at a price of 4.26, with a previous close of 3.72. The stock has fluctuated within a day range of 3.68 to 4.33, while its 52-week range spans from 1.61 to 9.50.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.